Table 8 Comparison between baseline patient demographic and disease characteristics of PRO cohort and non-PRO cohort
Total, n = 587 | PRO Cohort, n = 309 | Non-PRO Cohort n = 278 | P-valuea | |
|---|---|---|---|---|
Age in years, mean (SD) | 15.03 (3.10) | 14.99 (2.74) | 15.08 (3.46) | 0.73 |
Categorical age in years, n (%) | 0.15 | |||
2 to 4.9 | 4 (0.68) | 0 (0.00) | 4 (1.44) | |
5 to 10.9 | 58 (9.88) | 29 (9.39) | 29 (10.43) | |
11 to 14.9 | 176 (29.98) | 98 (31.72) | 78 (28.06) | |
15 to 21.9 | 349 (59.45) | 182 (58.90) | 167 (60.07) | |
Sex, n (%) | 0.08 | |||
Female | 276 (47.02) | 156 (50.49) | 120 (43.17) | |
Male | 311 (52.98) | 153 (49.51) | 158 (56.83) | |
Race/Ethnicity, n (%) | 0.23 | |||
Hispanic | 119 (20.27) | 54 (17.48) | 65 (23.38) | |
Non-Hispanic Black | 59 (10.05) | 31 (10.03) | 28 (10.07) | |
Non-Hispanic White | 338 (57.58) | 189 (61.17) | 149 (53.60) | |
Other and Unknown | 71 (12.10) | 35 (11.33) | 36 (12.95) | |
Histology, n (%) | 0.48 | |||
Nodular sclerosis | 449 (76.49) | 240 (77.67) | 209 (75.18) | |
Mixed cellularity | 33 (5.62) | 13 (4.21) | 20 (7.19) | |
NOS | 98 (16.70) | 52 (16.83) | 46 (16.55) | |
Lymphocyte-rich | 7 (1.19) | 4 (1.29) | 3 (1.08) | |
Stage, n (%) | 0.19 | |||
Stage IIB with Bulk | 121 (20.61) | 67 (21.68) | 54 (19.42) | |
Stage III | 113 (19.25) | 63 (20.39) | 50 (17.99) | |
Stage IVA | 167 (28.45) | 76 (24.60) | 91 (32.73) | |
Stage IVB | 186 (31.69) | 103 (33.33) | 83 (29.86) | |
B symptoms, n (%) | 0.13 | |||
No | 162 (27.60) | 75 (24.27) | 87 (31.29) | |
Yes | 418 (71.21) | 231 (74.76) | 187 (67.27) | |
Unknown | 7 (1.19) | 3 (0.97) | 4 (1.44) | |
Bulkb, n (%) | 0.29 | |||
No | 172 (29.30) | 82 (26.54) | 90 (32.37) | |
Yes | 411 (70.02) | 225 (72.82) | 186 (66.91) | |
Unknown | 4 (0.68) | 2 (0.65) | 2 (0.72) | |
Large mediastinal mass (LMA)b, n (%) | 0.15 | |||
No | 263 (44.80) | 128 (41.42) | 135 (48.56) | |
Yes | 323 (55.03) | 180 (58.25) | 143 (51.44) | |
Unknown | 1 (0.17) | 1 (0.32) | 0 (0.00) | |
Bone marrow disease, n (%) | 0.75 | |||
No | 497 (84.67) | 263 (85.11) | 234 (84.17) | |
Yes | 90 (15.33) | 46 (14.89) | 44 (15.83) |